Pfizer-BioNTech Begins Late-Stage Clinical Vaccine Trials on Children aged 5 to 11

Pfizer-BioNTech announced that it is expanding its clinical trials for children ages below 12 years old.

Pfizer COVD-19 vaccine will begin its testing across a group of 4,500 kids ages 5 to 11 years old in the United States, Finland, and Spain using a low dosage.

Today marks an important next step in our efforts to understand the safety and immune response of our COVID-19 vaccine,” Dr. Bill Gruber, SVP of Clinical Research and Development at Pfizer, said in a statement.

“In the coming weeks, we plan to initiate Phase 2/3 in children 2-4 years of age and children as young as six months,” he added.

According to Pfizer, younger trial participants whose age was under 5 years old will receive a 3-microgram dose in a two-shot regimen and 10 micrograms for kids aged between five and 11 years old.

Pfizer’s COVID-19 vaccine received final approval by the US Centers for Disease Control and Prevention for use in children ages 12 to 15 in May.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.